Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C, Oudard S. Vano YA, et al. Among authors: tricard t. Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4. Lancet Oncol. 2022. PMID: 35390339 Clinical Trial.
[Ablative therapy in kidney cancer: Indications].
Tricard T, Tsoumakidou G, Lindner V, Garnon J, Albrand G, Cathelineau X, Gangi A, Lang H. Tricard T, et al. Prog Urol. 2017 Nov;27(15):926-951. doi: 10.1016/j.purol.2017.07.245. Epub 2017 Aug 30. Prog Urol. 2017. PMID: 28869173 Review. French.
[Ablative therapy in urology: Good practice and perspective].
Gangi A, Cathelineau X, Tricard T, Lang H. Gangi A, et al. Among authors: tricard t. Prog Urol. 2017 Nov;27(15):994-1014. doi: 10.1016/j.purol.2017.08.008. Epub 2017 Sep 27. Prog Urol. 2017. PMID: 28958771 Review. French.
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A. Martinez Chanza N, et al. Among authors: tricard t. BMC Cancer. 2021 Dec 2;21(1):1292. doi: 10.1186/s12885-021-08990-3. BMC Cancer. 2021. PMID: 34856936 Free PMC article. Clinical Trial.
Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.
Gaillard V, Lhuillier A, Bigot C, Pierard L, Trensz P, Burgy M, Schuster C, Malouf G, Fritsch A, Lang H, Tricard T, Borchiellini D, Geoffrois L, Barthelemy P. Gaillard V, et al. Among authors: tricard t. Support Care Cancer. 2022 Aug;30(8):6583-6591. doi: 10.1007/s00520-022-07088-1. Epub 2022 Apr 29. Support Care Cancer. 2022. PMID: 35484315
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Lu X, Vano Y, Helleux A, Su X, Lindner V, Davidson G, Mouawad R, Spano JP, Rouprêt M, Elaidi R, Compérat E, Verkarre V, Sun C, Chevreau C, Bennamoun M, Lang H, Tricard T, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG. Lu X, et al. Among authors: tricard t. Clin Cancer Res. 2023 Apr 3;29(7):1279-1291. doi: 10.1158/1078-0432.CCR-22-2133. Clin Cancer Res. 2023. PMID: 36374555
Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.
Davidson G, Helleux A, Vano YA, Lindner V, Fattori A, Cerciat M, Elaidi RT, Verkarre V, Sun CM, Chevreau C, Bennamoun M, Lang H, Tricard T, Fridman WH, Sautes-Fridman C, Su X, Plassard D, Keime C, Thibault-Carpentier C, Barthelemy P, Oudard SM, Davidson I, Malouf GG. Davidson G, et al. Among authors: tricard t. Cancer Res. 2023 Sep 1;83(17):2952-2969. doi: 10.1158/0008-5472.CAN-22-3034. Cancer Res. 2023. PMID: 37335139
Minimally invasive nephron-sparing treatments for T1 renal cell cancer in patients over 75 years: a comparison of outcomes after robot-assisted partial nephrectomy and percutaneous ablation.
Lehrer R, Cornelis F, Bernhard JC, Bigot P, Champy C, Bruyère F, Rouprêt M, Doumerc N, Bensalah CK, Olivier J, Audenet F, Tricard T, Parier B, Durand X, Durand M, Charles T, Branger N, Surlemont L, Xylinas E, Beauval JB, Barral M. Lehrer R, et al. Among authors: tricard t. Eur Radiol. 2023 Dec;33(12):8426-8435. doi: 10.1007/s00330-023-09975-5. Epub 2023 Jul 19. Eur Radiol. 2023. PMID: 37466710
80 results